We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £290,278
Plant-based diets, health and fitness programmes for those interested in veganism to improve their health and wellbeing. Skinny Bitch's book has sold more than 1.1m copies and is available in 6 languages. Readers of the book include celebrities such as Eva Longoria and Jessica Alba. Ellen DeGeneres has stated that the Skinny Bitch book is the reason she became vegan. The company is now expanding their brand further by offering their content through online guides and blogs. Skinny Bitch is also intending to generate revenue via vegan supplements produced in the US to be sold through their website and third party e-commerce channels.
days to go: Expired investment: £75,810
Urban is a wellness app that allows customers to book massages, beauty treatments, personal training and more at the customer's doorstep in 60 minutes. The company's practitioners are already operating in London, Paris, Manchester and Birmingham covering all aspects of wellness, from massage to mindfulness and beyond. Urban has delivered over 650,000 appointments till date, witnessed £43 million in cumulative sales value since August 2018, onboarded 3,800 partner practitioners, and saw 7,300+ reviews on Apple app store with an average rating of 4.8/5 stars. It will use the investment to drive towards Operating Expense (OpEx) profitability by the end of Q1 2021, reach EBITDA positive by the end of 2021, and scale into new markets through remote expansion.
days to go: Expired investment: £5,877,517
Bua Fit is easy to use, a simple way to book web application for outdoor fitness classes. It eliminates all the trouble by connecting the trainers to clients for group fitness classes and gives the customers a diversity of trainers. The company has been a finalist in The Great British Entrepreneurial Challenge, has a network of 100 trainers and 42% active user rate since launch. With the proceeds, the company will earn more users, more trainers, more revenue, invest in product development and expand the team.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £205,378
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £215,946
WELD is a fitness company on a mission to make on-demand health, fitness and wellbeing available to all ages & abilities. The company allows users and instructors to set the time and place for the training session, rent out their home or commercial spaces for activities, or interact 1-2-1 online. This approach, the company believes, helps personal trainers, hit by the Covid-19 lockdown, find clients. WELD also allows trainers to set their prices and keep 90% of their fees, and lets customers enjoy a 2% commission on referrals for every future session taken in perpetuity. WELD aims to tap into the $94 billion global fitness and wellness market that grew 8.7% from 2018/19. The company's primary target audience is Generation Z that, the company believes, embraced wellness. WELD will use the investment to improve its platform, boost marketing and plug the fitness & wellness gap. 

Pitch Rated

56%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £199,227
Receive an affordable massage at home and on-demand by easily booking straight from an app. Since the start of year, Urban Massage has delivered more than 114,000 massages and received a 4.85/5 or above rating for the level of treatment provided to their customers. The company has successfully launched in Birmingham, Manchester and Paris with an Annualised Run Rate (ARR) of 3,300% from June 2014 and in June 2018, an ARR of £10.4m.
days to go: Expired investment: £3,491,730
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph